AstraZeneca COVID-19 vax to carry warning on immune disorder
The update on adverse events comes as ATAGI recalculates the risk of TTS for different age groups
Product information for AstraZeneca’s COVID-19 vaccine, Vaxzevria, has been updated to include fresh warnings about the potential risk of a rare immune disorder, the TGA says.
The medicines watchdog says this is in response to a growing number of adverse event reports of Guillain-Barré syndrome (GBS) in patients administered the viral-vector vaccine.
Investigations by local authorities and overseas drug regulators, however, “have so far been unable to establish a clear link between GBS and Vaxzevria”, the TGA said.
As of 22 August, it had received 89 reports mentioning GBS occurring after the vaccination, the TGA said.
